

1

2 **Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19:**
3 **A Complementary Approach to Population Surveys**

4

5 Hassan Alkharaan^{1#}, Shaghayegh Bayati^{5#}, Cecilia Hellström⁵, Annika Olsson², Karin
6 Lindahl^{2,4}, Gordana Bogdanovic³, Soo Aleman^{2,4}, Georgios Tsilingaridis¹, Patricia De
7 Palma¹, Sophia Hober⁶, Anna Månberg⁵, Peter Nilsson⁵, Elisa Pin^{5#}, Margaret
8 Sällberg Chen^{1#}

9

10 ¹Karolinska Institutet, Department of Dental Medicine, 14152, Stockholm, Sweden

11 ²Karolinska University Hospital, Department of Infectious Diseases, 14186,
12 Stockholm, Sweden

13 ³Karolinska University Hospital, Department of Clinical Microbiology, 14186,
14 Stockholm, Sweden

15 ⁴Karolinska Institutet, Department of Medicine, 14186, Stockholm, Sweden

16 ⁵Division of Affinity Proteomics, Department of Protein Science, School of
17 Engineering Sciences in Chemistry, Biotechnology and Health (CBH), KTH Royal
18 Institute of Technology, SciLifeLab, Stockholm, Sweden

19 ⁶Division of Protein Technology, Department of Protein Science, KTH Royal Institute
20 of Technology, Stockholm, Sweden

21

22 #These authors contributed equally

23

24 **Running title:** Salivary IgG to SARS-CoV-2 After Mild COVID-19

25 **Corresponding author:** Professor Margaret Sällberg Chen

26 **Word count: 198 (abstract) 3487 (total)**

27 **Figure and table count: 3 figures, 3 tables, 3 supplementary figures.**

28 *Footnote page*

29

30 **Conflict of interest statement:** NO

31 **Financial support statement:** This study was supported by grants from Region
32 Stockholm, Knut and Alice Wallenberg foundation, Science for Life Laboratory
33 (SciLifeLab), Erling-Persson family foundation (to SH).

34 **This study has not been presented any conference or meeting**

35 **Corresponding author contact information** Professor Margaret Sällberg Chen,
36 Karolinska Institutet, Sweden. Email: Margaret.Chen@ki.se

37

38

39 **Abstract**

40 **Background:** Declining humoral immunity in COVID-19 patients and possibility of
41 reinfections has raised concern. Mucosal immunity particularly salivary antibodies
42 could be short-lived. However, long-term studies are sparse.

43 **Methods:** Using a multiplex bead-based array platform, we investigated antibodies
44 specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins
45 in 256 saliva samples from convalescent patients 1-9 months after symptomatic
46 COVID-19 (n=74, Cohort 1), undiagnosed individuals with self-reported
47 questionnaires (n=147, Cohort 2), and individuals sampled pre-pandemic time (n=
48 35, Cohort 3).

49 **Results:** Salivary IgG antibody responses in Cohort 1 (mainly mild COVID-19) were
50 detectable up to 9 month recovery, with high correlations between spike and
51 nucleocapsid specificity. At 9 months, IgG remained in saliva in majority as seen in
52 blood serology. Salivary IgA was rarely detected at this timepoint. In Cohort 2,
53 salivary IgG and IgA responses were significantly associated with recent history of
54 COVID-19 like symptoms. Salivary IgG also tolerated temperature and detergent pre-
55 treatments.

56 **Conclusions:** Unlike SARS-CoV-2 salivary IgA that appeared short-lived, the
57 specific IgG in saliva appears stable even after mild COVID-19 as noted for blood
58 serology. The non-invasive saliva-based SARS-Cov-2 antibody testing with self-
59 collection at homes may thus serve as a complementary alternative to conventional
60 blood serology.

61

62 **Keywords:** COVID-19, saliva, antibody, serology, convalescence, immunoassay

63 **Introduction**

64 The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreake
65 in an abrupt fashion since it was reported in Wuhan, China, in late December 2019
66 (1), and obligated the World Health Organization to declare a global health
67 emergency which escalated the concern to a pandemic situation on March 2020. As
68 of Mars 2021, SARS-CoV-2 had infected over 114 million cases and caused up to
69 2.5 million global deaths (2). The human adaptive immune system plays a key role to
70 eliminate and memorize infectious microbes by launching a cascade of physiological
71 activities that brings to the activation of B and T lymphocytes. B lymphocytes are
72 responsible for producing antibodies that recognize and neutralize SARS-CoV-2
73 antigens in order to eradicate the infection and have shown to play a vital role in
74 protecting against re-infections in animal and humans (3–5). IgG, IgA, and IgM
75 antibodies, all principal contributors of humoral immunity, are activated against
76 SARS-CoV-2 and detected in the circulating blood of more than 90% of infected
77 individuals from the 11-13 day post-symptom onset (PSO) (6–8). Currently, the
78 SARS-CoV-2 immunity is under extensive examinations; a recent study showed that
79 circulating antibodies post-SARS-CoV-2 infection can persist up to 8 months (9), and
80 other previous studies show this immunological memory persists for a certain period
81 followed by a slight decay, especially in asymptomatic infected individuals (10–14).

82 Oral and nasal cavities are considered the main gate for SARS-CoV-2 virus entry,
83 and saliva secretory antibodies may be the first immunity arm that combat the
84 infection by recognizing the virus. Salivary antibodies to SARS-CoV-2 can be
85 detected early after symptom onset and may persist for up to at least three months
86 post infection (8,10,12). Hence, saliva sampling could be a sensible and non-invasive
87 way to indicate SARS-CoV-2 exposure. Similar to the previous SARS-CoV and

88 MERS-CoV, the spike protein (S) of SARS-CoV-2 recognizes the angiotensin-
89 converting enzyme 2 (ACE2) receptor and uses it as a key entry to attack the host
90 cells (15–17). Antibodies play an important role in resolving acute SARS-CoV-2
91 infection (11,18) but differential features of anti-SARS-CoV-2 antibodies negatively
92 impacting COVID-19 severity in hospitalized patients is also described, especially
93 related to complement deposition and systemic inflammation (19). Understanding the
94 dynamics and durability of antibody memory to SARS-CoV-2 is an instrumental step
95 to manage the pandemic, and even useful in deploying vaccination strategies.
96 However, as the mucosal immunity is known to be short-lived, the durability of SARS-
97 CoV-2 specific antibodies in saliva could be limited, and whether they permit
98 detection 3-4 month after infection (8,10) is of great interest.

99 In this study, we exploited a highly sensitive and specific multiplex SARS-CoV-2
100 serology platform previously validated for seroprevalence studies (20) to investigate
101 SARS-CoV-2 antibodies in the saliva. Samples from patients with diagnosis of mild
102 coronavirus disease (COVID-19) in the convalescence phase, at 1- 9 months after
103 diagnosis of COVID-19; and from undiagnosed individuals with or without history of
104 COVID-19 symptoms, were analysed and compared to pre-pandemic samples. Our
105 data indicate that spike-specific IgG reactivity is detectable in saliva in vast majority
106 of patients 1 - 9 months post infection. This result was similar to that detected by
107 blood serology performed in the clinical diagnostic laboratory. The IgA reactivity on
108 the other hand was short-lived in saliva, detectable only the first 3 months. Moreover,
109 IgG and IgA reactivity to both spike and nucleocapsid antigens significantly
110 correlated with a history of COVID-19 like symptoms in undiagnosed individuals.

111

112 **Materials and methods**

113 **Experimental Design**

114 We applied a bead-based serology assay to detect IgG and IgA to SARS-CoV-2
115 proteins in saliva samples to evaluate its performance. The assay method is
116 originally developed for detection of SARS-CoV-2 specific IgG in serum and plasma
117 (20). Salivary IgG and IgA responses to five different SARS-CoV-2 antigens (three
118 spike proteins and two nucleocapsid proteins) were first tested. The antigens'
119 performance in classifying positive and negative samples was evaluated for the
120 single antigens as well as for antigens combined in panels. Best performing
121 representations of spike and nucleocapsid were chosen in subsequent assessments.

122

123 **Cohort Design**

124 The study was approved by the human ethical authority (dnr 2020-01702, 2020-
125 06381) and complied with the declaration of Helsinki. All participants were recruited
126 after signing informed consent forms for this observational study. Saliva samples
127 (total n=256) were collected and arranged in following groups. Cohort 1:
128 convalescence COVID-19 samples (n=74) of 72 patients (2 participants donated
129 twice at 6 months apart) diagnosed with COVID-19 during March-April 2020, were
130 collected from June to December 2020; Cohort 2: samples from undiagnosed
131 individuals donated during May-Nov 2020 (n=147); Cohort 3: anonymous saliva
132 samples were from 2018 before the COVID-19 outbreak (pre-pandemic, n=35).

133 All convalescent patients (Cohort 1) had COVID-19 diagnosis confirmed by SARS-
134 CoV-2 RT-PCR, except one patient who had positive SARS-CoV-2 antibodies at four
135 time points in the convalescence phase. Seroconversion was tested by clinical
136 SARS-CoV-2 blood serology assays (described below). The patients were recruited

137 from the department of Infectious Diseases, Karolinska University Hospital (n=65),
138 and University Dental Clinic of Karolinska Institutet (n=7). Clinical demographic data
139 of convalescent patients was compiled from medical journal records or questionnaire,
140 and used in subgroup analysis. Among 72 patients, 95.8% had mild COVID-19,
141 without hospitalization due to COVID-19 symptoms. Three were admitted to hospital
142 for purpose of only isolation, and three were admitted due to COVID-19 symptoms. In
143 the latter group, two were hospitalized without any required oxygen treatment and
144 one received maximum 1.5 litre oxygen treatment during the hospitalization,
145 indicating no severe disease outcome. The time-points of serum and saliva samples
146 collection were grouped according to time post symptom onset (PSO), i.e. (i) PSO
147 less than 3 months. (ii) PSO of 3-8 months. (iii) PSO of 9 months. Cohort 2
148 constitutes of anonymous participants visiting the premises of University Dental Clinic
149 of Karolinska Institutet or Eastman Institute Stockholm during the study time, such as
150 patients, staff, or relatives to them. A questionnaire was used to collect COVID-19
151 related symptom information for sub-group analysis of undiagnosed samples into (i)
152 Symptomatic (ii) Non-symptomatic, based on their past 3 months health condition
153 before sampling.

154

155 **Saliva samples collection**

156 Expecterated unstimulated whole saliva samples were used throughout this study. All
157 samples were self-collected using standardized instructions and sample tubes
158 provided by this study, processed and stored at -80 within 24 hr. Salivary stability
159 tests were performed on samples subgroups to evaluate the antibody reactivity using
160 samples treated with 1% Triton X-100 for 1 hour at room temperature or heat-treated
161 at 56 C for 30 min in water bath to allow viral inactivation (19). Eighteen antibody-

162 positive from Cohort 1 and 10 antibody-negative samples from Cohort 2 were
163 included in the comparison. Incubation at room temperature for one to three days
164 was also tested in five samples to simulate the standard circumstances of mailed-in
165 saliva self-collection procedure. Saliva samples from convalescent patients (Cohort
166 1) were collected on the same day as venous blood during a COVID-19 follow-up
167 examination at the department of Infectious Diseases, Karolinska University Hospital.

168

169 **Clinical serology tests**

170 Paired serum samples of all convalescent patients were tested by Dept. of Karolinska
171 University Hospital Clinical Microbiology Laboratory. Three automated and one in-
172 house diagnostic methods were used under the study period of included
173 convalescence blood samples - SARS-CoV2-IgG test iFlash 1800 YHLO (CLIA),
174 LIAISON® SARS-CoV-2 S1/S2 IgG test DiaSorin (CLIA), and SARS CoV-2 IgG in-
175 house ELISA for samples taken prior to June 2020 mainly early convalescence
176 samples (<9month). The Elecsys® Anti-SARS-CoV-2 antibody test Roche (ECLIA)
177 was used for all late convalescence samples (9-month). YHLO determines the
178 antibodies against SARS-CoV-2 nucleocapsid and spike protein, DiaSorin against
179 spike protein, whilst Elecsys®, and in-house ELISA to the recombinant nucleocapsid
180 protein. The tests use different techniques such as chemiluminescence
181 immunoassay (CLIA), electrochemiluminescence immunoassay (ECLIA), and
182 enzyme-linked immunoassay (ELISA).

183

184 **Antigen Production**

185 The proteins were produced as following: 1) Spike-f as spike trimers comprises the
186 prefusion-stabilized spike glycoprotein ectodomain is expressed in HEK cells and

187 purified using a C-terminal Strep II tag, 2) Spike S1 domain was expressed in CHO
188 cells and purified using C-terminal HPC4-tag, 3) Spike RBD domain was expressed
189 in HEK cells and purified using the mFc C tag; 4) nucleocapsid, one full-length
190 version and 5) one nucleocapsid C-terminal chain were each expressed in *E.coli* and
191 purified using a C-terminal His-tag (21,22).

192

193 **SARS-CoV-2 antibody detection by a bead-based assay**

194 The analysis of salivary antibodies was performed as previously described (20) with
195 a few modifications. Briefly, each antigen was diluted to a final concentration of 80
196 µg/ml (100mM) with 2-(N-morpholino) ethanesulfonic acid buffer, pH 4.5
197 (SigmaAldrich) and immobilized on uniquely color-coded bead type (bead ID)
198 (MagPlex-C, Luminex corp.). The antigen-immobilized beads were then pooled to
199 form the bead array. Besides the viral antigens, anti-human IgG (309-005-082,
200 Jackson ImmunoResearch), anti-human IgA (800-338-9579, Bethyl), and the EBV
201 EBNA1 protein (ab138345, Abcam) were also included as sample loading controls.

202 Saliva samples were diluted 1/5 in assay buffer composed of 3% bovine serum
203 albumin (w/v), 5% non-fat milk (w/v) in 1×PBS supplemented with 0.05 % (v/v)
204 Tween20 (VWR, 437082Q) and incubated with the bead array for 1 hour at room
205 temperature and 650 RPM rotation. Afterwards, the antigen-antibody complexes
206 were cross-linked by adding 0.2% paraformaldehyde (AlfaAesar, 30525-89-4) in PBS
207 0.05% Tween 20 (PBS-T) for 10 min at room temperature. Detection was performed
208 by applying R-phycoerythryne-conjugated anti-human IgG (H10104, Invitrogen)
209 diluted 0.4 µg/mL, or R-phycoerythryne-conjugated anti-human IgA (800-338-9579,
210 Bethyl) diluted 0.2 µg/mL in PBS-T for 30 minutes at room temperature. Finally, the

211 read-out was performed by using a FlexMap3D system and the xPONENT software
212 (Luminex Corp.).

213 **Statistical analysis.**

214 Statistics and visualizations of the multiplex bead array generated data were
215 performed using R (version 3.6.1) with RStudio (version 1.2.1335) and the additional
216 packages heatmap (1.0.10), reshape2 (1.4.3). In-house developed functions were
217 used for instrument file import and quality control. The bead array results were
218 acquired as Median Fluorescent Intensity (MFI) per sample and bead identity. A
219 cutoff for seropositivity was calculated per antigen as the mean + 7x SD of 12
220 negative pre-pandemic reference samples carefully selected based on their signal
221 intensity distribution. GraphPad Prism Version 9.0.0 (86) was used for the
222 nonparametric comparisons Mann-Whitney test and Spearman correlation analysis.
223 Datasets also initially underwent normality distribution testing. N1 Chi-squared test
224 was used for comparisons of binomial datasets in MedCal software calculator. Two-
225 sided p-values <0.05 were considered significant. Descriptive analyses were made
226 on clinical characteristics and the number of observations, presented as numbers
227 and percentages.

228 **Results**

229 *Salivary antibody reactivity to SARS-CoV-2 proteins*

230 The assay performance was validated by comparing the capability of each of the five
231 antigens included in the array to classify convalescent samples <3 mo–9 mo (Cohort
232 1, n=74) and pre-pandemic samples (Cohort 3, n=35), of which 12 samples from
233 Cohort 3 were used to set the assay cut-offs. Among the five antigens included in the
234 assay, spike foldon (Spike-f) and C-terminal fragment (NC-C) showed the best

235 performance (88% and 61% sensitivity respectively, and 100% specificity) in
236 classifying SARS-CoV-2 saliva samples of the convalescence cohort from the pre-
237 pandemic cohort (**Table 1**). We also evaluated the antigen panel in all possible
238 combinations of 2 and 3 proteins, considering as *positive* a sample that showed
239 reactivity to both antigens in a panel-of-two antigens, and at least to two out of three
240 antigens in a panel-of-three antigens (**Table S1 and 2**). There, the best performance
241 among the panels was reached by the Spike-f, S1, RBD triple combination, showing
242 70.3% sensitivity and 100% specificity. Hence, the absolute best performance was
243 shown to be reached by Spike-f as single antigen (88% sensitivity, 100% specificity)
244 in this COVID-19 convalescent and pre-pandemic saliva collection. IgA reactivities to
245 the included proteins were identified only in a minority of cases, with higher
246 prevalence of reactivity to Spike-f (12%) (**Table S3**).

247

248 *Serum and salivary antibody reactivity overtime post Covid-19*

249 As shown in **Table 2**, Cohort 1 were mainly patients who have had mild COVID-19
250 and were grouped according to duration past their diagnosis. Some were hospitalized
251 for isolation mainly, but none received oxygen treatment or required ventilation
252 related treatment. All individuals were free from respiratory symptoms at the 9-month
253 follow-up but in a minority across all three groups various general residual symptoms
254 were still noted (data not shown). As shown in **Table 3**, the vast majority of serum
255 samples up to 9 months convalescence were still tested positive in clinical SARS-
256 CoV-2 serology, with high seroprevalence across the whole time span of collection.
257 Interestingly, paired saliva samples from Cohort 1 patients tested with the multiplex
258 bead-array showed that the positivity rate of anti- Spike-f IgG in saliva remained
259 remarkably high and in similar range (100%-87.5%) as noted for serum antibodies

260 (88.9%-96.9) throughout from early (<3 months) to late convalescence group (9
261 months) (**Table 3, Figure 1a**). However, the NC-C specific IgG in saliva dropped
262 significantly after 3 months (from 88.9% to 60.6-50.0%). As stated earlier, specific
263 IgA responses to these antigens were detected only in a minority of the saliva
264 samples, and was enriched in early convalescence (<3months, 44.4% for Spike-f and
265 11% for NC-C), while dropping to less than 10% in later convalescent samples
266 ($p<0.01$).

267 Moreover, salivary IgG to Spike-f and NC-C showed to be highly correlated in this
268 cohort ($r=0.88$, $p<0.0001$, Spearman correlation test), with concordant serostatus in
269 the majority of samples (**Figure 1b**). Significant albeit moderate correlations were
270 also seen between IgA to Spike-f and NC-C ($r=0.62$, $p<0.001$), and between Spike-f
271 specific IgA and IgG ($r=0.45$, $p<0.001$) (Figure 1b).

272

273 *Salivary antibody reactivity to SARS-CoV-2 in healthy donors is associated with the*
274 *recent history of COVID-19 like symptoms.*

275 Next, we applied this assay platform to evaluate a second independent cohort -
276 Cohort 2. Participants here were self-reporting symptom-free individuals visiting the
277 University Dental Clinic's premises of Karolinska Institutet and the Eastman Institute
278 in Stockholm. A total of 147 individuals from May to November 2020 participated in
279 and donated saliva samples. Samples were collected and tested using the same
280 standard operating protocol as for Cohort 1. Shown in **Figure 2a**, and based on
281 antigen-specific cutoffs calculated on 20 negative controls, antibody reactivities to
282 Spike-f and NC-C in this cohort were as following: IgG were detected in 14% to either
283 Spike-f or NC-C, while 11% had detectable IgG to both antigens; for IgA, 10% and
284 6% of the samples showed reactivity to Spike-f and NC-C respectively, while only 5%

285 showed reactivity to both. Salivary positivity was particularly enriched among
286 participants with self-reported recent history of COVID-19-like symptoms (14 days to
287 3 months prior to sampling time). Significant reactivities of IgG ($p=0.004$, and $p=0.01$)
288 and IgA ($p<0.0001$, and $p=0.044$) to either Spike-f or NC-C was found to associate
289 with recent history of symptoms compared to pre-pandemic controls (**Figure 2a**).

290 A correlation analysis (**Figure 2b**) gave similar result as for Cohort 1, with highest
291 reported correlation between salivary IgG to Spike-f and NC-C ($r=0.81$, $p<0.0001$,
292 Spearman correlation test). Significant albeit moderate correlations were also seen
293 between IgA to Spike-f and NC-C ($r=0.73$, $p<0.001$), and IgG and IgA to Spike-f
294 ($r=0.49$, $p<0.001$), and Spike-f IgA to NC-C IgG ($r=0.53$, $p<0.001$).

295

296 *Saliva antibody stability – the influence of inactivation pre-treatment and room*
297 *temperature*

298 Next the effects of inactivation treatment with 1% Triton X-100 or heat-treatment at
299 56 C, as well as room temperature storage (identical aliquots left out for indicated
300 time) on the antibody results were determined (**Figure 3**). Both 1% Triton X-100 and
301 heat treatment showed slight or no change in the cutoff calculated based on the ten
302 included negative controls. A good correlation between treated and non-treated
303 samples was noted (**Figure 3 and S1**), with a few exceptions of single samples that
304 show a drop in IgG reactivity. Simulation with room temperature storage (22°C)
305 showed a slow decay in IgG signal intensity in positive samples (blue) over time, with
306 the signals of negative samples remain low and stable (grey). Based on these data,
307 inactivation by Triton X-100 or heat treatment treatments seems to have little effect
308 on saliva samples. However, antibody decay variations showed slight IgG signal
309 reduction by each day of room temperature storage.

310 **Discussion**

311 Comprehensive antibody testing and the subsequent interventions they generate are
312 essential to monitoring and control SARS-CoV-2 transmission. The present study
313 demonstrates that SARS-CoV-2 specific IgG in saliva after mild COVID-19 can serve
314 as a complementary measure of exposure or immunity to SARS-CoV-2, particularly
315 due to their frequent concurrence with serum IgG responses. Key findings include 1)
316 SARS-CoV-2-specific mucosal salivary antibodies co-exist with the circulating blood
317 antibodies up to 9 months post-natural infection in the majority of participants (88% in
318 saliva vs. 97% in blood); 2) natural infection induces salivary antibodies to recognize
319 both viral spike and nucleocapsid proteins; 3) the response correlates significantly to
320 recent Covid-19-like symptom history in undiagnosed individuals; 4) saliva IgG is
321 relatively stable tolerating both biosafety required temperature and detergent pre-
322 treatment. All together representing a non-invasive approach suitable for population-
323 based immunity surveys. Ideally, if the latter is sampled at home and mailed to the
324 lab, it can help protect vulnerable persons at risk for severe COVID-19 by sparing the
325 need to visit the laboratory units for blood draws. This is an appealing way to test
326 persons, in pandemic situation, and definitely a complementary test for conventional
327 blood IgG assay. Our data also showed that sample inactivation with either heat
328 treatment or Triton X-100 might be both safe options for testing saliva sample in the
329 lab, causing very little to no variation on the assay performance.

330

331 Severe COVID-19 symptoms have been shown to cause strong antibody responses
332 in 99% of convalescence individuals, but published data show also that the antibody
333 responses tend to disappear faster in cases with mild symptoms (6, 9, 16, 19).
334 Possible reason for this is that tests developed earlier during the pandemic were

335 based on detection in samples from severe COVID-19 cases rather than individuals
336 with mild symptoms, hence sensitivity was not optimal (23). Further, many of the
337 early developed tests are using the nucleocapsid as antigen and antibodies targeting
338 this part of the virus has been shown to decline faster (24) as also was detected
339 here. In this study, we deliberately recruited convalescence samples from mild
340 COVID-19 patients, showing that the multiplex antibody platform used here was
341 capable of detecting specific SARS-CoV-2 antibodies in saliva up to 9 months post
342 infection. In the present study, the clinical blood test results that were compared with
343 the saliva reactivities are from certified patient diagnostics (including anti-N pan-Ig
344 ECLIA), showed high performance in detecting late convalescence blood samples. In
345 fact, our result is in line with a recent South Korean group reporting this diagnostic
346 antibody assay is, among several others, effective in detecting SARS-CoV-2
347 antibodies in blood (90%) of individuals up to 8 months after either asymptomatic
348 infection or reporting mild-symptoms (25). The persistence of salivary IgG to
349 structural viral proteins in the saliva samples after 9 months recovery from mild
350 COVID-19 is intriguing, and possibly explained by a secondary exposure or spill-over
351 from the blood. More studies are therefore warranted to clarify this. In relation to it,
352 the mucosal antibody response is triggered slightly earlier upon infection (10).
353 Information is still limited about the duration and kinetics of mucosal antibodies
354 secreted into the mouth and nose, particularly in this patient group. A sensitive
355 salivary antibody detection assay with the capability to identify infections with various
356 severities would contribute to improving the current understanding of mucosal
357 antibodies to SARS-CoV-2. For instance, such studies may compare low versus high
358 avidity antibodies and their relation to neutralization or disease enhancement
359 (10,26,27).

360

361 The notion that antibodies to previously known coronaviruses may block SARS-CoV-
362 2 has raised a concern about whether these antibodies are functional. However, such
363 antibodies are also known to be protective only for about 6 months after the infection,
364 therefore would have disappeared in most cases of SARS-CoV-2 (28,29), Comparing
365 saliva samples using pseudo-neutralizing assay in ACE-2 cross-blocking
366 experiments will therefore be interesting. Other applications for quantitative and
367 qualitative saliva antibody assays include immunity studies to elucidate vaccine-
368 induced mucosal immunity, including the response to antigens representing new
369 virus mutants and vaccine-induced escape mutants. Since mouth and nose are the
370 first port of entry for SARS-CoV-2, sensitive and accurate methods for quantitative
371 measurements of such local mucosal immunity will lead to better means to combat
372 this virus.

373

374 One limitation of our study was the relatively small sample size and the
375 predominantly male population. Another weakness is blood samples were not
376 analyzed same way as saliva, and as several diagnostic assays were used only
377 binary data is given. Also, because of the cross-sectional design, we could not obtain
378 baseline or longitudinal saliva samples. Moreover, we could not assess individual
379 possibilities of re-exposure or re-infection. However, it is unlikely that humoral
380 immunity was boosted because in Stockholm, where the study takes place, the
381 period June-Nov 2020 (second-wave) showed an increase in the daily incidence rate
382 of COVID-19 from 30 to 400 cases/100,000 population (30). In conclusion, despite
383 waning immunity concerns, the present study shows how our multiplex bead-based

384 immunoassays can detect antibodies against SARS-CoV-2 in saliva collected at 9
385 months after infection in the majority of mildly symptomatic persons.

386

387 **Authors contributions:** E.P., A.M., P.N., M.S.C. conception and design of the study.
388 H.A., S.B., A.M., A.O., collected the material and performed the experiments. H.A.,
389 S.B., C.H. A.M., E.P., M.S.C. analyzed the data. E.P., AM, P.N., and M.S.C.
390 supervised the work. K.L., S.A. G.B. S.H. contributed with material and data
391 interpretations, H.A., S.B., E.P., and M.S.C. wrote the manuscript. All authors
392 reviewed and revised the manuscript critically.

393

394 **Acknowledgments**

395 All study participants who took interest in this study.

396 **References:**

- 397 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus
398 from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727–
399 33.
- 400 2. University of Johns Hopkins. Coronavirus Resource Center [Internet]. Available
401 from: <https://coronavirus.jhu.edu/map.html>
- 402 3. Krammer F. SARS-CoV-2 vaccines in development. *Nature* [Internet]. 2020 Oct
403 22;586(7830):516–27. Available from: [http://dx.doi.org/10.1038/s41586-020-](http://dx.doi.org/10.1038/s41586-020-2798-3)
404 2798-3
- 405 4. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of
406 an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against
407 SARS-CoV-2. *Cell*. 2020;182(3):713–721.e9.
- 408 5. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et
409 al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care
410 Workers. *N Engl J Med* [Internet]. 2021 Feb 11;384(6):533–40. Available from:
411 <http://www.nejm.org/doi/10.1056/NEJMoa2034545>
- 412 6. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V,
413 McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion
414 in humans. *Nat Med* [Internet]. 2020;26(7):1033–6. Available from:
415 <http://dx.doi.org/10.1038/s41591-020-0913-5>
- 416 7. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann
417 AJ, et al. The receptor-binding domain of the viral spike protein is an
418 immunodominant and highly specific target of antibodies in SARS-CoV-2
419 patients. *Sci Immunol*. 2020;5(48):1–10.
- 420 8. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody

- 421 responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*.
422 2020;26(6):845–8.
- 423 9. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological
424 memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*
425 (80-) [Internet]. 2021 Feb 5;371(6529):eabf4063. Available from:
426 <https://www.sciencemag.org/lookup/doi/10.1126/science.abf4063>
- 427 10. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of
428 serum and saliva antibody responses to SARS-CoV-2 spike antigens in
429 COVID-19 patients. *Sci Immunol*. 2020;5(52):1–21.
- 430 11. Baumgarth N, Nikolich-Žugich J, Lee FE-H, Bhattacharya D. Antibody
431 Responses to SARS-CoV-2: Let’s Stick to Known Knowns. *J Immunol*
432 [Internet]. 2020 Nov 1;205(9):2342–50. Available from:
433 <http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.2000839>
- 434 12. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et
435 al. COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody
436 Responses in Saliva. Loeffelholz MJ, editor. *J Clin Microbiol* [Internet]. 2020
437 Dec 17;59(1):1–13. Available from: <https://jcm.asm.org/content/59/1/e02204-20>
- 438 13. Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, et
439 al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-
440 Prevalence Communities and Reveal Durable Humoral Immunity. *Immunity*
441 [Internet]. 2020 Nov;53(5):925–933.e4. Available from:
442 <https://linkinghub.elsevier.com/retrieve/pii/S1074761320304453>
- 443 14. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and
444 immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*
445 [Internet]. 2020 Aug 18;26(8):1200–4. Available from:

- 446 <http://www.nature.com/articles/s41591-020-0965-6>
- 447 15. Gui M, Song W, Zhou H, Xu J, Chen S, Xiang Y, et al. Cryo-electron
448 microscopy structures of the SARS-CoV spike glycoprotein reveal a
449 prerequisite conformational state for receptor binding. *Cell Res* [Internet]. 2017
450 Jan 23;27(1):119–29. Available from: <http://www.nature.com/articles/cr2016152>
- 451 16. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et
452 al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked
453 by a Clinically Proven Protease Inhibitor. *Cell* [Internet]. 2020 Apr;181(2):271–
454 280.e8. Available from:
455 <https://linkinghub.elsevier.com/retrieve/pii/S0092867420302294>
- 456 17. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-
457 converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*
458 [Internet]. 2003 Nov;426(6965):450–4. Available from:
459 <https://doi.org/10.1038/nature02145>
- 460 18. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM,
461 Weiskopf D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute
462 COVID-19 and Associations with Age and Disease Severity. *Cell* [Internet].
463 2020;183(4):996–1012.e19. Available from:
464 <https://doi.org/10.1016/j.cell.2020.09.038>
- 465 19. Opeyemi S. Adeniji¹, Leila B. Giron¹, Netanel F Zilberstein,² Maliha
466 W.Shaikh², Robert A Balk², James N Moy², Christopher B. Forsyth², Ali
467 Keshavarzian², Alan 10 Landay² MA-M. COVID-19 Severity Is Associated with
468 Differential Antibody Fc-mediated Innate Immune Functions. *bioRxiv Prepr*
469 [Internet]. 2021; Available from:
470 <https://www.biorxiv.org/content/10.1101/2021.01.11.426209v1?s=09>

- 471 20. Rudberg A-S, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et
472 al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare
473 workers in Sweden. *Nat Commun* [Internet]. 2020 Dec 8;11(1):5064. Available
474 from: <http://www.nature.com/articles/s41467-020-18848-0>
- 475 21. Tegel H, Steen J, Konrad A, Nikdin H, Pettersson K, Stenvall M, et al. High-
476 throughput protein production - Lessons from scaling up from 10 to 288
477 recombinant proteins per week. *Biotechnol J* [Internet]. 2009 Jan;4(1):51–7.
478 Available from: <http://doi.wiley.com/10.1002/biot.200800183>
- 479 22. Kanje S, Enstedt H, Dannemeyer M, Uhlén M, Hober S, Tegel H.
480 Improvements of a high-throughput protein purification process using a
481 calcium-dependent setup. *Protein Expr Purif* [Internet]. 2020
482 Nov;175(June):105698. Available from:
483 <https://doi.org/10.1016/j.pep.2020.105698>
- 484 23. Takahashi S, Greenhouse B, Rodríguez-Barraquer I. Are Seroprevalence
485 Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased? *J*
486 *Infect Dis* [Internet]. 2020 Nov 9;222(11):1772–5. Available from:
487 <https://academic.oup.com/jid/article/222/11/1772/5898481>
- 488 24. Havervall S, Jernbom Falk A, Klingström J, Ng H, Greilert-Norin N, Gabrielsson
489 L, et al. SARS-CoV-2 induces a durable and antigen specific humoral immunity
490 after asymptomatic to mild COVID-19 infection. *medRxiv* [Internet].
491 2021;2021.01.03.21249162. Available from:
492 <https://doi.org/10.1101/2021.01.03.21249162>
- 493 25. Choe PG, Kim K-H, Kang CK, Suh HJ, Kang E, Lee SY, et al. Antibody
494 Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection.
495 *Emerg Infect Dis* [Internet]. 2021 Mar;27(3):928–31. Available from:

- 496 https://wwwnc.cdc.gov/eid/article/27/3/20-4543_article.htm
- 497 26. Wen J, Cheng Y, Ling R, Dai Y, Huang B, Huang W, et al. Antibody-dependent
498 enhancement of coronavirus. *Int J Infect Dis* [Internet]. 2020 Nov;100:483–9.
499 Available from: <https://doi.org/10.1016/j.ijid.2020.09.015>
- 500 27. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent
501 enhancement and SARS-CoV-2 vaccines and therapies. *Nat Microbiol*
502 [Internet]. 2020 Oct 9;5(10):1185–91. Available from:
503 <http://dx.doi.org/10.1038/s41564-020-00789-5>
- 504 28. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al.
505 Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
506 antibody. *Nature* [Internet]. 2020;583(7815):290–5. Available from:
507 <http://dx.doi.org/10.1038/s41586-020-2349-y>
- 508 29. Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al.
509 Seasonal coronavirus protective immunity is short-lasting. *Nat Med* [Internet].
510 2020;26(11):1691–3. Available from: [http://dx.doi.org/10.1038/s41591-020-](http://dx.doi.org/10.1038/s41591-020-1083-1)
511 [1083-1](http://dx.doi.org/10.1038/s41591-020-1083-1)
- 512 30. Folkhälsomyndighetens. Folkhälsomyndighetens veckorapporter om covid-19.
513 [Internet]. 2020. p. June-November. Available from:
514 <https://www.folkhalsomyndigheten.se/folkhalsorappo>

515

516 **Figure legends**

517 **Figure 1.** Measurement of IgG and IgA to Spike-f (soluble trimeric form of the spike
518 glycoprotein stabilized in the pre-fusion conformation) and NC-C (nucleocapsid C-
519 terminal fragment) of SARS-CoV2 in saliva of convalescence patients (Cohort 1). (A)
520 Multiplex assay measured signal scores on indicated immunoglobulins to Spike-f and

521 NC-C in cohorts of pre-COVID samples (n=35), and convalescent patient samples at
522 indicated month post infection (n=74). The data is expressed in median fluorescence
523 index (MFI) and plotted using dot plots where each dot is one individual sample.
524 Horizontal bars denote the mean and vertical line represents standard errors. Mann-
525 Whitney U test for significance was performed (B) Spearman correlation analysis with
526 coefficient indicated for respective antibody specificity pairs. n.s = not significant.

527

528 **Figure 2.** SARS-CoV2 specific IgG and IgA in saliva of undiagnosed study
529 participants (Cohort 2) measured by same method as in Figure 1. Samples were sub-
530 grouped by participant reported COVID-like symptoms the past 14 days - 3 months
531 prior to sampling (Cohort 2). (A) Multiplex assay measured signal scores on indicated
532 immunoglobulins to Spike-f and NC-C in cohorts of pre-COVID samples (n=35), and
533 convalescent patient samples at indicated month post infection (n=146). The data is
534 expressed in median fluorescence index (MFI) and plotted using dot plots where
535 each dot is one individual sample. Horizontal bars denote the mean and vertical line
536 represents standard errors. Mann-Whitney U test for significance was performed (B)
537 Spearman correlation analysis with coefficient indicated for respective antibody
538 specificity pairs. n.s = not significant.

539

540 **Figure 3.** Stability tests of saliva samples subjected to heat (HT), 1% Triton-X-100
541 (Triton), or left for indicated time in room temperature. (A) SARS-CoV2 specific IgG
542 and IgA reactivities in convalescence saliva samples (Pos) or Pre-pandemic saliva
543 samples (Neg) were tested either untreated (Untreated) or after heat inactivation at
544 56°C for 30 min (HT), or after Triton-X-100 inactivation (final 1% volume/volume) for
545 60 min (Triton). Reactivities to Spike-f respective NC-C antigens are shown as box

546 plots with each dot representing one single sample. (B) Convalescence saliva
547 samples (blue) or pre-pandemic saliva samples (grey) were aliquoted and placed in
548 room temperature (22°C) at indicated time points, thereafter snap frozen and tested
549 in same assay run for measurement of SARS-CoV2 specific IgG to spike or
550 nucleocapsid.

551

552 **Supplementary materials**

553 **Figure S1.** Correlation analysis comparing inactivation by heat, Triton-X-100, and
554 untreated conditions as shown in Figure 3A.

Table 1. Single antigen specificity and sensitivity in detecting SARS-CoV-2 IgG in convalescent saliva (1-9 month PSO) and pre-pandemic saliva samples.

		Convalescent (N=74)			Pre-pandemic (N=23) [#]		
Antigen	Host	Sensitivity [%]	Pos	Neg	Specificity [%]	Pos	Neg
Spike-f	HEK	88	65	9	100	0	23
S1	CHO	61	45	29	100	0	23
RBD	HEK	69	51	23	96	1	22
NC	<i>E. coli</i>	49	36	38	100	0	23
NC-C	<i>E. coli</i>	61	45	29	100	0	23

[#]Another 12 independent pre-pandemic saliva samples were used to establish assay cut-offs.

Table 2. Demographic characteristics of convalescence samples of Cohort 1, grouped by the time-points of post symptom onset (PSO) at which the samples were taken.

Parameters	Convalescent saliva samples (n=74)		
	< 3 months (n=9)	3-8 months (n=33)	9 months (n=32)
Gender (F:M)	8:1	23:10	6:26
Age (years) median (range)	59 (48-67)	49 (20-63)	57 (45-78)
Hospitalization status (%)			
○ Never hospitalized			
○ Hospitalized for only isolation purpose	66.7 11	94 3	97 3
○ Hospitalized due to COVID-19 symptoms	22	3	0
Days PSO (Mean SD)	55 20	120 41	273 11


Table 3. Cohort B. Salivary antibodies to Spike or NC-C over time concurs with serum positivity in clinically validated SARS-Cov-2 antibody diagnostics

Convalescence (mo)	Serum Ab SARS CoV-2	Saliva IgG		Saliva IgA	
		Spike-f	NC-C	Spike-f	NC-C
<3	88.9%	100.0%	88.9%	44.4%	11.1%
3-8	90.9%	84.8%	60.6%**	6.3%***	3.1%**
9	96.9%	87.5%	50.0%***	9.7%***	6.5%***

Note: ** and *** indicate $p < 0.01$ and $p < 0.0001$ respective compared to clinical SARS-Cov-2 serum antibody diagnosis, determined by N-1 Chi-squared test (Campbell I, Statistics in medicine, 2007, Richardson JTE, Statistics in medicine, 2011). Ab (antibody). Spike-f (spike foldon), NC-C (nucleocapsid c-terminal chain).

Fig 1.

A.



B.




Fig 2.






Fig. 3

A.



B.



Supplementary Table 1. Combinations of 2 antigens. Specificity and sensitivity in detecting SARS-CoV-2 IgG in Cohort 1 samples (1-9 months convalescence).

		Positive controls (N=74)			Negative controls (N=23*)		
Antigen	Host	Sensitivity [%]	Negative result	Positive result	Specificity [%]	Negative result	Positive result
Spike-f S1	HEK CHO	60.8	29	45	100	23	0
Spike-f RBD	HEK HEK	68.9	23	51	100	22	0
Spike-f NC	HEK <i>E.Coli</i>	48.6	38	36	100	23	0
Spike-f NC-C	HEK <i>E.Coli</i>	60.8	29	45	100	23	0
S1 RBD	CHO HEK	68.9	23	51	100	23	0
S1 NC	CHO <i>E.Coli</i>	60.8	29	45	100	23	0
S1 NC-C	CHO <i>E.Coli</i>	60.8	29	45	100	23	0
RBD NC	HEK <i>E.Coli</i>	48.6	38	36	100	23	0
RBD NC-C	HEK <i>E.Coli</i>	60.8	29	45	100	23	0
NC NC-C	<i>E.Coli</i> <i>E.Coli</i>	48.6	38	36	100	23	0

Note. A sample is considered positive when classified positive for both antigens included in the panel.

* The negative samples included here are Cohort 3 excluded the 12 negative used for cutoff calculation

Supplementary Table 2. Combinations of 3 antigens. Specificity and sensitivity in detecting SARS-CoV-2 IgG in Cohort 1 samples (1-9 months convalescence).

		Positive controls (N=74)			Negative controls (N=23*)		
Antigen	Host	Sensitivity [%]	Negative result	Positive result	Specificity [%]	Negative result	Positive result
Spike-f	HEK	70.3	22	52	100	23	0
S1	CHO						
RBD	HEK						
Spike-f	HEK	62.2	28	46	100	23	0
S1	CHO						
NC	<i>E.Coli</i>						
Spike-f	HEK	64.9	26	48	100	23	0
S1	CHO						
NC-C	<i>E.Coli</i>						
S1	CHO	62.2	28	46	100	23	0
RBD	HEK						
NC	<i>E.Coli</i>						
RBD	HEK	58.1	31	43	100	23	0
NC	<i>E.Coli</i>						
NC-C	<i>E.Coli</i>						
S1	CHO	58.1	31	43	100	23	0
NC	<i>E.Coli</i>						
NC-C	<i>E.Coli</i>						
Spike-f	HEK	60.8	29	45	100	23	0
NC	<i>E.Coli</i>						
NC-C	<i>E.Coli</i>						
Spike-f	HEK	70.3	22	52	95.7	22	1
RBD	HEK						
NC-C	<i>E.Coli</i>						
S1	CHO	59.5	30	44	100	23	0
RBD	HEK						
NC-C	<i>E.Coli</i>						
Spike-f	HEK	67.6	24	50	95.7	22	1
RBD	HEK						
NC	<i>E.Coli</i>						

Note. A sample is considered positive when classified positive for two out of three antigens included in the panel.

* The negative samples included here are Cohort 3 excluded the 12 negative used for cutoff calculation



Supplementary Table 3. Single antigen specificity and sensitivity in detecting SARS-CoV-2 IgA in Cohort 1 samples (1-9 months convalescence).

		Positive controls (N=74)			Negative controls (N=23*)		
Antigen	Host	Sensitivity [%]	Negative result	Positive result	Specificity [%]	Negative result	Positive result
Spike-f*	HEK	16.2	62	12	95.7	22	1
S1	CHO	5.4	70	4	91.3	21	2
RBD	HEK	6.8	69	5	91.3	21	2
NC	<i>E. coli</i>	6.8	69	5	87.0	20	3
NC-C*	<i>E. coli</i>	5.4	70	4	91.3	21	2

* The negative samples included here are Cohort 3 excluded the 12 negative used for cutoff calculation

Fig. S1

IgG:



IgA:

